anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A multicenter, open-label, single-arm clinical study of KANUMA was conducted in 9 infants with LAL deficiency who had growth failure or other evidence of rapidly progressive disease prior to 6 months of age. The age range at entry was 1 to 6 months. Patients received KANUMA at 0.35 mg/kg once weekly for the first 2 weeks and then 1 mg/kg once weekly. Due to suboptimal clinical response, doses in all 6 surviving patients were escalated to 3 mg/kg once weekly, between 4 and 88 weeks (median 11 weeks) after starting treatment at 1 mg/kg.

The efficacy of KANUMA was assessed by comparing the survival of the 9 KANUMA-treated patients (followed in the open-label, single-arm trial) at 12 months of age to the survival in an untreated, historical cohort of 21 patients with a similar age at disease presentation and clinical characteristics. Of the 9 KANUMA-treated patients, 6 patients survived beyond 12 months of age, compared to 0 of 21 patients who survived in the historical cohort, all of whom had died by 8 months of age. The median age of the 6 surviving KANUMA-treated patients was 18.1 months (range 12 to 42.2 months).

Following initiation of treatment with KANUMA 1 mg/kg once weekly, weight-for-age (WFA) z-scores improved in 3 of 5 surviving patients with growth failure, and all 6 surviving patients demonstrated improvements in WFA z-scores following dose escalation to 3 mg/kg once weekly.

Continuation Treatment

Across Study 1 and another study, Study 3, in infants with rapidly progressive LAL Deficiency, 9 patients received successive dose escalations up to 5 mg/kg once weekly due to suboptimal clinical response [see Recommended Dosage (2.2)]. The median duration of exposure to 5 mg/kg for the 9 patients whose doses were escalated to 5 mg/kg once weekly was 33 months (range 27 to 39 months) for patients in Study 1 and 15 months (range 5 to 24 months) in Study 3.

Of the 9 patients whose KANUMA dose was escalated to 5 mg/kg once weekly, 6 were alive at their last follow up at 3 years, and 2 were alive at their last follow up at 5 years. Of these 9 patients, 6 experienced normalization of ALT and/or AST which had remained abnormal on the lower KANUMA dose.
PURPOSE: An siRNA which suppresses BC200 RNA activation and a pharmaceutical composition containing the same for suppressing tumor metastasis are provided to inhibit cancer cell migration and metastasis and to effectively treat cancer. CONSTITUTION: An siRNA which suppresses BC200 RNA(sequence number 1) activation has a base sequence of 5'-GUAACUUCCCUCAAAGCAA-3'(sequence number 2) or 5'- UUGCUUUGAGGGAAGUUAC-3'(sequence number 3). The siRNA additionally contains a dTdT base sequence at the 3'-end of the siRNA. A vector contains a polynucleotide which enables transcription of shRNA. The vector transcribes shRNA in a cell and the transcribed shRNA is converted into siRNA by cleavage using RNase III. A pharmaceutical composition for suppressing tumor metastasis contains the vector as an active ingredient. The composition additionally contains a pharmaceutically acceptable carrier. [Reference numerals] (AA) Negative control group siRNA
Functional abdominal bloating/distension (FAB/D) is a common functional bowel disorder that lacks effective treatment options. Rome IV was introduced in 2016. Studies have shown that bloating may affect about 30% general population and 96% of patients with functional gastrointestinal disorders (FGID).Transcutaneous electroacupuncture (TEA) as a new therapeutic method has great effect on functional gastrointestinal diseases such as functional dyspepsia and functional constipation. Research on TEA for FAB/D has not yet been explored. Thirty patients who fulfilled the Rome IV diagnostic criteria of FAB/D in the department of the second affiliated hospital of Xi'an jiaotong University.Inclusion criteria included: Symptoms of recurrent abdominal fullness, pressure, or a sensation of trapped gas (bloating), and/or measurable (objective) increase in abdominal girth (distention) more than 6 month；the main symptoms appeared in the past 3 months；Not taking related drugs; aged 18-65 years old；From January 2020 to December 2021; Sign informed consent. All patients were randomly assigned to 3 groups and received TEA at Zusanli (ST36) and Neiguan (PC6) with 3 diffrent parameter for 4weeks. The symptom severity score, abdominal girth, electrogastrogram (ECG) and orocecal transit time (OCTT) ,heart rate variability (HRV) ,rectal sensitivity and intestinal flora were recorded at baseline and after 2-week treatment, respectively. The symptom severity score was repeated at baseline and after 4-week treatment. Through the comparison of the index before and after TEA treatment to identify optimal stimulation parameters and explore its possible mechanism. The study was proved by the medical ethics committee of the Second Affiliated Hospital of Xi'an jiaotong University.
The present invention relates to a preparation technology and a production method for an integrated new formulation of an aluminite decoction, wherein the raw materials of active ingredients comprise: 3 parts by weight of aluminite, 9 parts by weight of raw rehmannia root, and 3 parts by weight of sophora flavescens. The production process of the integrated new formulation aluminite decoction comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of aluminite decoction is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of aluminite decoction can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of aluminite decoction can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
For participants randomized to the TOMOFIX system, preoperative planning will use the HKA radiograph. DICOM images will be transported to MEDICAD software program in which alignment angles and alignment correction will be calculated. The mMPTA will again be utilised to determine the accuracy of correction (primary outcome). The preop CT scan will also be used as per the BodyCAD system and the same indices calculated so as to minimise measurement bias between two different imaging modalities. However, the results of the preoperative 3D CT planning will not be made available to the operating surgeon, again to minimise bias between groups.
The present invention describes the composition of an animal feed additive containing a nutrient-rich fermented broth obtained by means of a fermentation process using a genetically modified microorganism. The non-pathogenic bacterium Corynebacterium glutamicum, which is of great commercial interest, has been modified to produce aminolevulinic acid (5-ALA) more efficiently. The nutritional medium obtained is rich in biomolecules, such as sugars, organic acids, amino acids including 5-ALA, vitamins, and nucleotides, inter alia. In addition, the inactivated bacterial biomass can be added together with the fermented broth, acting as a source of nutrients without harming the animals. When added to animal feed, this broth promotes a series of benefits such as improved growth and immunity, reduces the use of antibiotics and supports the metabolism. Animals, such as pigs, poultry, cattle and fish, have a commercial value and any gain generates a financial return.
The invention relates to a broad-spectrum antiseptic solution diluted in 1000ml of 0.9% isotonic sterile solution, to which is added 50g of bicarbonate powder until fully dissolved. Subsequently, 100ml of sodium hypochlorite is added at a concentration of 5%, until fully dissolved. Next, 15ml of chloramphenicol ophthalmic solution is added at a concentration of 5mg/ml. If the wound is very infected and damaged, 50ml of colourless, pure liquid soap is added. The aforementioned concentrations can be varied depending on the requirements of the wound to which it is to be applied. In addition, the frequency and period of use are also taken into account. The aim of the invention is to create a broad-spectrum antiseptic solution which is totally different from those available on the market for use in human and veterinary medicine and which could replace these products since it provides improved results owing to the mode of action and the mixture of components which, when dissolved in 0.9% isotonic saline solution, can more easily penetrate tissues, impregnating the cells of the tissue affected by the wound to be treated, without causing damage to said cells since the base is isotonic and does not induce cell death as happens with normal water. Moreover, the components are not as damaging, aggressive or toxic to cell tissues with which they come into contact, as is the case with other existing water-based antiseptic solutions. The above-mentioned components, which have never been mixed together for the same or a similar purpose, form a very broad-spectrum antiseptic solution, rendering same very effective for wounds infected by any colonising bacteria, parasite or fungus. Said colourless, pure liquid soap is essential for very severe wounds with a lot of dead tissue and pus or foreign bodies that require a soap solution in order to improve debridement during asepsis and antisepsis.
<P>PROBLEM TO BE SOLVED: To provide a technique for discharging a nonaqueous emulsion containing glycerol, or the like, as a continuous phase and having high viscosity as heavy foam.  <P>SOLUTION: An aerosol cosmetic product is constituted so that contents discharged are packed into either one space part in a two-chamber container separated by a movable diaphragm capable of separating the contents, and a compressed gas pressurized in order to push out the contents is packed into the other space part. The aerosol cosmetic product contains a gas for expanding the contents when the contents are discharged and the pressure of the compressed gas for pushing out is higher than gas pressure of gas contained in the contents. The gas pressure of gas contained in the contents is preferably 0.2-0.4 mpas and the pressure of compressed gas for pushing out is preferably higher by ≥0.05 mpas than gas pressure of gas contained in the contents. The viscosity of the contents in a state not containing the gas may be ≥20,000 mpas sec.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The invention relates to an integrated novel form preparation technology for Daikankyoto and a production method thereof. The effective components of the Daikankyoto comprise the following raw materials in parts by weight: 10 parts of Chinese rhubarb, 10 parts of mirabilite and 1 part of euphorbia kansui. The production process of the Daikankyoto comprises the steps of supersonic airflow pulverizing, alcohol water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spraying and drying, nanometer grinding, uniform high-pressure emulsification, nano particle preparation and the like. According to the invention, the multi-synergism, multi-target and other advantages embodied by a nano-carrier coupling technique are attached to apply. After the Daikankyoto is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The Daikankyoto can be taken by internally and externally feeding and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of human body. In addition, the Daikankyoto can be prepared into films and transdermal agents which are respectively attached to different parts of human body according to the midnight-noon ebb-flow and qi and blood flowing rule of human body and can be directly absorbed through skin.
An electrical cable of the present invention comprises a plurality of spaced, parallel flat conductors. Each of the plurality of flat conductors was previously integral with each immediately adjacent flat conductor. A dielectric material is holds the conductors in the spaced, parallel relationship. The dielectric material can be a polymer film, a nonwoven, or other polymer materials such as PTFE, or expanded PTFE. The cable of the present invention is made by providing first and second webs of dielectric materials and a third sheet of conductive material. The first and second web materials are bonded to the third sheet of conductive material in a face-to-face layered relationship thereby forming a bonded laminate. The bonded laminate is then incrementally stretched to separate the sheet of conductive material in to spaced, parallel flat conductors.
Each 20 mg and 40 mg omeprazole and sodium bicarbonate capsule contains 1,100 mg (13 mEq) of sodium bicarbonate. The total content of sodium in each capsule is 304 mg.

Chronic administration of bicarbonate with calcium or milk can cause milk-alkali syndrome. Chronic use of sodium bicarbonate may lead to systemic alkalosis, and increased sodium intake can produce edema and weight gain.

The sodium content of omeprazole and sodium bicarbonate products should be taken into consideration when administering to patients on a sodium-restricted diet or those at risk for developing congestive heart failure.

Avoid omeprazole and sodium bicarbonate in patients with Bartter's syndrome, hypokalemia, hypocalcemia, and problems with acid-base balance.
Central neuropathic pain (CNP) and musculoskeletal pain (MSP) are often comorbid with multiple sclerosis (MS), yet data on the emotional burden entailed by this comorbidity are very limited. We studied whether MS patients with CNP exhibited greater emotional burden and pain severity than those with MSP and whether this emotional burden was attributed to the MS, the chronic pain, or both. Participants were 125 MS patients (55 with CNP; 30 with MSP; 40 MS pain-free) and 30 healthy controls (HCs). Participants completed questionnaires assessing pain interference, pain catastrophizing, depression, anxiety, stress, hypervigilance, and chronic pain. Group comparisons and a two-step cluster analysis were performed, and the association between cluster membership and clinical group membership was evaluated. Chronic pain was stronger and more widespread in the CNP group than in the MSP group. Both pain groups had higher pain interference, pain catastrophizing, and stress compared to MS pain-free and HC groups. All MS groups had greater depression levels compared to HCs, and the CNP group had the highest anxiety level. The "high psychological distress" cluster comprised mainly participants with CNP (57%), and the "minimal psychological distress" cluster comprised mainly the MS pain-free and HC groups. In conclusion, CNP seems to induce greater emotional burden and pain severity than does MSP. Whereas depression may be attributed to MS, and anxiety to CNP, enhanced pain interference, catastrophizing, and stress may be attributed to the comorbidity of MS and chronic pain. Identifying these traits among MS patients and targeting them in management programs may contribute to more effective, individually based care.
Particulate matter (PM) is a leading cause of respiratory tract and cardiovascular disease in the United States and world-wide. Wood smoke particles (WSP) derived from wild land and other fires account for a significant fraction of ambient air PM. Health effects associated with WSP include acute bronchitis, asthma exacerbation, pneumonia, cough and systemic inflammation. While these effects are seen in both healthy and asthmatic individuals, many studies indicate that asthmatics have increased susceptibility to the effects of WSP. Though WSP-related effects on cardiovascular (CV) disease are less well documented, WSP do contribute to PM levels, and PM exposure is linked to CV health effects (changes in heart rate variability, vascular reactivity, and lipid profiles). WSP from wild land fires can cause abrupt increases in ambient air PM 2.5 levels (mean levels \~250µg/m3, peak levels \>1000 µg/m3). Avoidance of rapidly increasing PM air pollution due to wild land fires is not feasible, as many people cannot leave the burn region.

This is a screening protocol to ensure that there ultimately will be adequate subjects available for testing gamma tocopherol in an appropriate population. It will identify volunteers who have a ≥10% increase in %PMNs following WSP challenge over baseline values (SA1). This screening procedure will identify various risk factors that may increase risk of experiencing airway inflammation and related adverse health outcomes following WSP exposure. The GSTM1- genotype is a risk factor that has been extensively explored. Researchers at the CEMALB have reported that GSTM1- healthy volunteers (HVs) have increased inflammatory and systemic responses to O3 and various components of PM (LPS70 and Diesel exhaust particles). Using the 10% increase in %PMNs to define PMN responsiveness, results showed that GSTM1- volunteers had a 13 fold higher risk of being PMN responders to 0.06 ppm O3. When examining %PMNs as a continuous measure, it was observed that GSTM1- volunteers have increased airway PMN response O3 as well as increased airway and systemic PMN response to LPS70.

The researchers at the CEMALB have also examined various response features of 27 individuals (13 healthy, 4 allergic non asthmatics, 10 allergic asthmatics) defined as being responsive (R, n=18) or non-responsive (NR, n=9) to O3 based on airway PMN influx (%PMNs). Among the factors explored were inflammatory responses, baseline characteristics and gene expression profiles in recovered sputum cells. The researchers have also observed that within individuals, PMN response to O3 and LPS correlate, and anticipate that WSP will induce inflammatory responses via mechanisms similar to those for these pollutants.
The present study investigates effects of current focusing and pulse shape on threshold, dynamic range, spread of excitation and channel interaction in the time domain using cochlear implant stimulation. The study was performed on 20 adult guinea pigs using a 6-channel animal cochlear implant, recording was performed in the auditory midbrain using a multielectrode array. After determining the best frequencies for individual recording contacts with acoustic stimulation, the ear was deafened and a cochlear implant was inserted into the cochlea. The position of the implant was controlled by x-ray. Stimulation with biphasic, pseudomonophasic and monophasic stimuli was performed with monopolar, monopolar with common ground, bipolar and tripolar configuration in two sets of experiments, allowing comparison of the effects of the different stimulation strategies on threshold, dynamic range, spread of excitation and channel interaction. Channel interaction was studied in the temporal domain, where two electrodes were activated with pulse trains and phase locking to these pulse trains in the midbrain was quantified. The results documented multifactorial influences on the response properties, with significant interaction between factors. Thresholds increased with increasing current focusing, but decreased with pseudomonophasic and monophasic pulse shapes. The results documented that current focusing, particularly tripolar configuration, effectively reduces channel interaction, but that also pseudomonophasic and monophasic stimulation and phase duration intensity coding reduce channel interactions.
Subjects who are enrolled in the dose escalation treatment Periods of Part A may choose to only take part in the dose escalation treatment Periods 1-3, or may choose to also take part in the challenge Treatment Period (Period 4). If a subject chooses to participate in the dose escalation treatment Periods 1-3 only, or does not (at screening) meet the eligibility criteria specific to challenges (treatment Period 4), a new subject will be recruited for treatment Period 4 only and will be regarded as a replacement subject. The study will be conducted in three Parts. Total duration for participation will be approximately 19 weeks for subjects taking part in all three dose escalation treatment Periods and 23 weeks if a subject takes part in all four treatment Periods of Part A. For replacement subjects only taking part in the challenge treatment Period (Period 4), approximate study duration will be 10 weeks. Total duration for participation will be approximately 9 weeks for Part B and 12 weeks for Part C. The study will be conducted in up to 80 subjects.
FIELD: cosmetology. SUBSTANCE: invention relates to composition for oxidative keratine fibers coloring. Composition has 2-aminohydroxy-pyridine as the first coupling agent in combination with oxidizing base taken among para-phenylenediamines and/or paraaminophenols and the second coupling agent taken among derivatives of meta-aminophenol. Invention relates to also a method of coloring and dye set. Invention provides preparing agent for more stable coloring. EFFECT: improved properties of composition and method of coloring. 17 cl, 8 ex
Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.